Apr 27, 2020
Innovent Announces First Patient Dosed in a Pivotal Trial of Parsaclisib in Patients with Indolent Lymphoma in China
Jan 27, 2020
Global B-cell Non-Hodgkin's Lymphoma Market Review 2017-2019 and Forecast 2020-2028
Jan 14, 2020
John Theurer Cancer Center Investigators Report Transformative Results of CAR T-Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Dec 08, 2019
Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
Jul 15, 2019
Umbralisib (TG Therapeutics/Rhizen) Drug Overview & Product Profiles 2017-2018 & 2019-2026
Jul 12, 2019
Imbruvica (ibrutinib; AbbVie/Johnson & Johnson) Drug Overview & Product Profiles 2017-2026
Jul 11, 2019
Nordic Nanovector Completes Patient Enrolment Into Phase 1 Trial of Betalutin® in Diffuse Large B-cell Lymphoma (DLBCL)
Jul 11, 2019
Non-Hodgkin Lymphoma (NHL) Therapeutics Market to Record a CAGR of 7.4% During 2019-2024
Jun 17, 2019
Cellular Biomedicine Group Announces First Patient Dosing in Phase I Clinical Trial of Anti-CD20 CAR-T for Lymphoma in China
May 22, 2019
Genomic Testing Cooperative (GTC) and Collaborators to Present Data Resulting from its Proprietary DNA and RNA Profiling of Diffuse Large B-cell Lymphoma at the 2019 ASCO Annual Meeting
Dec 03, 2018
Nordic Nanovector: Additional Preclinical Studies With CD37-targeting Radioimmunotherapies for B-cell Malignancies Presented at ASH
Nov 26, 2018
Two Posters on DB102 (Enzastaurin) Presented at the American Society of Hematology Annual Meeting
Oct 31, 2018
Global Non-Hodgkin Lymphoma Therapeutics Market Outlook to 2025 featuring Novartis, Merck, GSK, Bayer, Pfizer, Celgene, and many more
Oct 25, 2018
Nordic Nanovector's Betalutin® Receives Promising Innovative Medicine (PIM) Designation in the UK for the Treatment of Follicular Lymphoma
Sep 11, 2018
Global B-cell non hodgkin lymphoma drugs market 2018-2022
Jul 11, 2018
AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Blood Cancer Diffuse Large B-Cell Lymphoma (DLBCL) and Ongoing Ibrutinib Clinical Program
Jul 11, 2018
Janssen Provides Update on IMBRUVICA® (ibrutinib) Phase 3 PHOENIX Trial in Newly Diagnosed Non-Germinal Center B Cell (Non-GCB) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL)
Jun 15, 2018
JAK Inhibitors Associated with Aggressive Lymphoma
May 31, 2018
Curis Announces FDA Fast Track Designation for Fimepinostat (CUDC-907) Development in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
May 03, 2018
Forty Seven, Inc. Granted Fast Track Designation for 5F9 for the Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma